HJS  >> Vol. 6 No. 1 (January 2017)

    血清CA19-9异常增高的胆总管结石7例诊治体会
    Experience of Diagnosis and Treatment of 7 Cases of Common Bile Duct Stones with Abnormal Increase of Serum CA19-9

  • 全文下载: PDF(645KB) HTML   XML   PP.8-12   DOI: 10.12677/HJS.2017.61002  
  • 下载量: 237  浏览量: 460  

作者:  

刘立民,张宗明,刘 卓,张 翀,于宏伟,刘子旭,朱明文,宋蒙蒙,赵 月:首都医科大学北京电力医院普外科,北京

关键词:
胆总管结石急性胆管炎血清CA19-9Common Bile Duct Stones Acute Cholangitis Serum CA19-9

摘要:

血清CA19-9是一种常见的肿瘤标志物,其升高多见于各种消化系统恶性肿瘤患者,尤其是胆管癌、胰腺癌,对于鉴别胆道良、恶性疾病具有重要参考价值。胆道良性疾病患者,血清CA19-9异常升高者少见。本文结合7例血清CA19-9异常升高的胆总管结石患者的诊治体会,深入探讨胆总管结石患者血清CA19-9异常升高的病因、诊断和治疗,以期有效提高血清CA19-9异常升高的胆道良性疾病患者的诊治效果、避免胆道恶性肿瘤的误诊和误治。

Serum CA19-9 is one of the most common tumor markers whose elevation is common in patients with various malignant tumors of digestive system, especially bile duct carcinoma, pancreatic cancer, which has important reference value in the differential diagnosis of benign and malignant biliary diseases. Patients with benign biliary tract disease, abnormal elevated serum CA19-9 are rare. Based on our experience of abnormal increase of serum CA19-9 in 7 patients with choledocholithiasis, this paper will further investigate the etiology, diagnosis and treatment of bile duct stones in patients with abnormal serum CA19-9 increased, so as to effectively improve the diagnosis and treatment effect of the biliary tract benign disease patients with abnormal elevated serum CA19-9, and to avoid misdiagnosis and mistreatment of biliary tract malignant tumor.

文章引用:
刘立民, 张宗明, 刘卓, 张翀, 于宏伟, 刘子旭, 朱明文, 宋蒙蒙, 赵月. 血清CA19-9异常增高的胆总管结石7例诊治体会[J]. 外科, 2017, 6(1): 8-12. http://dx.doi.org/10.12677/HJS.2017.61002

参考文献

[1] Tanaka, N., Okada, S., Ueno, H., et al. (2000) The Usefulness of Serial Changes in Serum CA19-9 Levels in the Diagnosis of Pancreatic Cancer. Pancreas, 20, 378-382. https://doi.org/10.1097/00006676-200005000-00007
[2] 朱良如, 侯晓华. 消化系统肿瘤标志物的检测及临床应异[J]. 中国实用内科杂志, 2002, 22(9): 574-576.
[3] Akimoto, S., Banshodani, M., Nishihara, M., et al. (2016) Acute Cholecystitis with Significantly Elevated Levels of Serum Carbohydrate Antigen 19-9. Case Reports in Gastroenterology, 10, 410-416. https://doi.org/10.1159/000448068
[4] Sheen-Chen, S.M., Sun, C.K., Liu, Y.W., et al. (2007) Extremely Elevated CA19-9 in Acute Cholangitis. Digestive Diseases and Sciences, 52, 3140-3142. https://doi.org/10.1007/s10620-006-9164-7
[5] Koprowski, H., Stepleweski, Z., Mitchell, K., et al. (1979) Colorectal Carcinoma Antigens Detected by Hybridoma Antibodies. Somatic Cell and Molecular Genetics, 5, 957-972. https://doi.org/10.1007/BF01542654
[6] 孔宪涛. 肿瘤特异抗原的研究现状及检测[J]. 中华检验医学杂志, 2000, 23(1): 56-58.
[7] 尹大龙, 张树庚, 刘连新, 等. CA19-9在良性胆道疾病中表达的临床意义[J]. 中国普通外科杂志, 2009, 18(8): 864-866.
[8] Wong, D., Ko, A.H., Hwang, J., et al. (2008) Serum CA19-9 Decline Compared to Radiographic Response as a Surrogate for Clinical Outcomes in Patients with Metastatic Pancreatic Cancer Receiving Chemotherapy. Pancreas, 37, 269- 274. https://doi.org/10.1097/MPA.0b013e31816d8185
[9] 曾立云, 宋逢林, 彭瑛. 胰腺癌血清CA19-9 和CEA的表达及意义[J]. 中国普通外科杂志, 2008, 17(9): 926-928.
[10] 王怀志, 赵玉亭, 赵国强, 等. 胃癌患者血清CA19-9, CA242联合检测[J]. 中国普通外科杂志, 2004, 13(9): 711- 712.
[11] 王自正, 李少华, 马伦, 等. 现代医学标记免疫学[M]. 北京: 人民军医出版社, 2000: 57.
[12] Ito, S. and Gejyo, F. (1999) Elevation of Serum CA19-9 Levels in Benign Diseases. Internal Medicine, 38, 840-841. https://doi.org/10.2169/internalmedicine.38.840
[13] Yu, H., Yu, T.N. and Cai, X.J. (2013) Tumor Biomarkers: Help or Mislead in the Diagnosis of Xanthogranulomatous Cholecystitis?—Analysis of Serum CA19-9, Carcino-Embryonic Antigen, and CA12-5. Chinese Medical Journal (English), 126, 3044-3047.
[14] Ince, A.T., Yıldiz, K., Baysal, B., et al. (2014) Roles of Serum and Biliary CEA, CA19-9, VEGFR3, and TAC in Differentiating between Malignant and Benign Biliary Obstructions. The Turkish Journal of Gastroenterology, 25, 162- 169. https://doi.org/10.5152/tjg.2014.6056
[15] Lourdusamy, V., Tharian, B. and Navaneethan, U. (2015) Biomarkers in Bile-Complementing Advanced Endoscopic Imaging in the Diagnosis of Indeterminate Biliary Strictures. World Journal of Gastrointestinal Endoscopy, 7, 308- 317.
[16] Mann, D.V., Edwards, R., Ho, S., et al. (2000) Elevated Tumor Marker CAl9-9: Clinical Interpretation and Influence of Obstructive Jaundice. European Journal of Surgical Oncology, 26, 474-479. https://doi.org/10.1053/ejso.1999.0925